Drug Pricing Investigation: AbbVie - Humira and Imbruvica

Thumbnail Image
Serial Number
Levin Center Identifier
Document Date
2021-05-18
Report Length
57 pages
Policy Agendas Project Major Code
Policy Agendas Project Minor Code
Additional, Minority, Dissenting Views
Found Using Methodology
Yes
Subcommittee(s)
Commission(s)
Idependent Author(s)
Brief Executive Summary
House Committee on Oversight and Reform produced this report detailing AbbVie Inc.'s actions in repeatedly increasing prices for two prescription drugs, Humira (adalimumab) and Imbruvica (ibrutinib). Humira, a widely used drug for autoimmune diseases, generated $16 billion in U.S. net revenue for AbbVie in 2020, with the current price approximately 470% higher than its 2003 launch. Imbruvica, treating certain cancers, now costs over $181,529 annually, an 82% increase since its 2013 introduction. The report finds price increases resulted in substantial corporate profits and executive enrichment while adversely affecting American patients and taxpayers.
Press Releases and Contextual Information
Related Hearings
Authors–Congress Members
Authors–Staff Members
Authors–Ex Officio Members
Authors–Additional, Minority, Dissenting Views
Citation